Liposomal formulation with thiazolic compounds against bacterial efflux pumps

Area of Science:

• Medicinal Chemistry
• Antimicrobial Resistance
• Drug Delivery

Background:

• Efflux pumps are a major mechanism of multidrug resistance (MDR) in bacteria.
• Eugenol derivatives are explored for antimicrobial properties.
• Liposomal encapsulation can improve drug delivery and efficacy.

Purpose of the Study:

• To evaluate liposome-encapsulated eugenol-based thiazolic derivatives against efflux pump-carrying bacteria.
• To assess their antibacterial activity and antibiotic potentiation.
• To investigate their potential as efflux pump inhibitors.

Main Methods:

• Minimum Inhibitory Concentration (MIC) determination for antibacterial activity and antibiotic potentiation.
• Ethidium bromide assay to analyze efflux pump inhibition in Staphylococcus aureus strains.
• Testing against Pseudomonas aeruginosa and Staphylococcus aureus MDR strains.

Main Results:

• Eugenol-based thiazoles showed no significant direct antibacterial activity (MICs ≥1024 µg/mL).
• Compounds potentiated gentamicin activity against P. aeruginosa and norfloxacin/gentamicin against S. aureus MDR strains.
• Compound LF 26 significantly reduced ethidium bromide uptake and potentiated antibiotics in S. aureus strains with NorA and MepA efflux pumps.

Conclusions:

• Eugenol-based thiazoles can potentiate existing antibiotics against MDR Gram-negative and Gram-positive bacteria.
• Compound LF 26 shows promise as an efflux pump inhibitor, particularly against S. aureus strains expressing NorA and MepA.
• Further development of these compounds could offer new strategies to combat antibiotic resistance.